This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BIVN-401, Virostat, Methylene Blue
Description: Suvus is currently used in several European countries to inactivate pathogens, especially certain viruses, in fresh frozen plasma. Suvus, especially when irradiated by light, prevents the replication of DNA and RNA in pathogens by oxidizing guanine. Suvus has shown viricidal activity in vitro, especially against viruses such as HIV and West Nile Virus.
Deal Structure: Bioenvision obtained global license rights fromOklahoma Medical Research Foundation (OMRF) for the right to develop and market Virostat for anti-viral indications.
In October 2007, Genzyme acquired Bioenvision.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Additional information available to subscribers only: